Our Work
Latham & Watkins Advises Juno Therapeutics in JW Therapeutics’ US$100 Million Series B Financing
July 9, 2020
A cross-border life sciences team represented the immunotherapy biopharmaceutical company in the transaction.
JW Therapeutics has announced the completion of a US$100 million Series B round financing. The investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec. This round of financing brings the total capital raised to over US$200 million.
Latham & Watkins LLP represents Juno Therapeutics in the transaction with a life sciences team consisting of Bay Area partner Judith Hasko, Shanghai associate Louise Deng and Bay Area associate Peggy Ni.